- Salt reduction is beneficial for people with Type 2 diabetes
- Pioglitazone raises risk of bladder cancer by 63%
- Diabetes 2015 – Care in Crisis
- Diabetic Retinopathy
- People with diabetes not offered dietary advice
- Medication errors in hospitals
- First ever mandatory care standards to improve the level of care of children and young people with diabetes
- Insulin Analogues and Cancer – A Possible Link That Needs Further Investigation
- The Safety of Insulin Analogues – should patients be concerned?
- Bellagio Report
- Health Select Committee – IDDT gives evidence
- Warnings about ‘human’ insulin from the manufactuers, Novo Nordisk and Aventis
- Zyban – Safety precautions from the Committee on Safety of Medicines
- Novo Nordisk discontinue some GM ‘human’ insulins
- IQWiG: No proof long-acting insulin analogues outperform human insulin for Type 2 diabetes
- Cochrane Review – long-acting analogues vs NPH insulin in Type 2 diabetes
- IQWiG: Short-acting insulin analogues are not superior to regular ‘human’ insulin in Type 2 diabetes
- IQWiG: Rapid-acting analogues are not superior to ‘human’ insulin for Type 1 diabetes
- About IQWiG
- Cochrane review of short-acting insulin analogues versus regular human insulin in patients with diabetes mellitus
- Cochrane review of ‘human’ vs animal insulin
- About Cochrane Reviews
- Insulin – A Voice for Choice By Arthur Teuscher
Insulin Analogues and Cancer – A Possible Link That Needs Further Investigation
This is the title of a patient information sheet issued by the European Association for the Study of Diabetes [EASD] on June 26th, 2009.
As regular visitors to our website are already aware, there have been concerns for some time that the long-term safety of insulin analogues is unknown and insulin analogues have a greater potential for cell multiplication, with a possible increased risk of cancer due to their greater similarity to insulin-like growth factor 1 [IGF-1] . The EASD has investigated these concerns for Lantus [glargine] and published several studies looking at groups of people who are using insulin to treat their diabetes – people with Type 1 and Type 2 diabetes. Levemir [detemir] was introduced more recently and Professor Gale, Editor of Diabetolgia the journal in which the studies have been published, states: "We have yet to examine this in the same way as Lantus."
The EASD recognise the limitations of these studies but the authors state in their press release: "We believe that people are entitled to know that the use of Lantus insulin might be associated with greater risk, but this must also be balanced against the possibility that we might be causing unnecessary alarm by raising these concerns."
As a result, the EASD has issued a press release and also issued an information sheet for patients.
Press release: http://www.diabetologia-journal.org/cancer.html#press
Patient Information sheet: http://www.diabetologia-journal.org/cancer.html#info
Further information and details of the EASD studies are available at:
Other studies of interest on this topic include:
Insulin analogues display IGF-1-like mitogenic and anti-apoptotic activities in cultured cancer cells.
Diabetes Metab Res Rev 2009; 25; 41-49
Insulin analogues: fears, facts and fantasies.
Diabetes Metab Res Rev 2009; 25; 50-51
Novel insulin analogues and its mitogenic potential.
Diabetes, Obesity and Metabolism, 8, 2006, 611-620
IDDT reminds everyone that it is very important not to stop taking your insulin. If you have concerns about the analogue insulins or wish to consider changing your insulin, then there are alternatives so you do have a choice and you should discuss this with your doctor.